Zacks: Aevi Genomic Medicine, Inc. (GNMX) Given Average Recommendation of “Hold” by Brokerages

Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating. Aevi Genomic Medicine’s rating score has declined by 20% from 90 days ago as a result of various analysts’ ratings changes.

Brokers have set a twelve-month consensus target price of $5.00 for the company and are forecasting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Aevi Genomic Medicine an industry rank of 240 out of 265 based on the ratings given to related companies.

An institutional investor recently raised its position in Aevi Genomic Medicine stock. Renaissance Technologies LLC boosted its holdings in Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by 515.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,600 shares of the biotechnology company’s stock after buying an additional 78,400 shares during the period. Renaissance Technologies LLC owned approximately 0.16% of Aevi Genomic Medicine worth $112,000 as of its most recent filing with the Securities and Exchange Commission. 20.44% of the stock is owned by institutional investors and hedge funds.

Aevi Genomic Medicine stock traded down $0.09 during mid-day trading on Tuesday, reaching $1.60. The company’s stock had a trading volume of 61,089 shares, compared to its average volume of 112,000. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $2.65.

Aevi Genomic Medicine (NASDAQ:GNMX) last released its quarterly earnings data on Tuesday, March 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. sell-side analysts forecast that Aevi Genomic Medicine will post -0.63 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.

Leave a Reply